Check for updates

OPEN ACCESS

EDITED AND REVIEWED BY Zhongheng Zhang, Sir Run Run Shaw Hospital, China

*CORRESPONDENCE Anna S. Messmer anna.messmer@insel.ch

SPECIALTY SECTION This article was submitted to Intensive Care Medicine and Anesthesiology, a section of the journal Frontiers in Medicine

RECEIVED 14 February 2023 ACCEPTED 15 February 2023 PUBLISHED 03 March 2023

CITATION

Meyhoff TS, Wichmann S and Messmer AS (2023) Editorial: Fluid overload in the critically ill. *Front. Med.* 10:1166202. doi: 10.3389/fmed.2023.1166202

COPYRIGHT

© 2023 Meyhoff, Wichmann and Messmer. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Editorial: Fluid overload in the critically ill

Tine S. Meyhoff^{1,2}, Sine Wichmann^{2,3} and Anna S. Messmer^{4*}

¹Department of Intensive Care, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, ²Collaboration for Research in Intensive Care (CRIC), Copenhagen, Denmark, ³Department of Anaesthesia and Intensive Care, Nordsjællands Hospital, University of Copenhagen, Copenhagen, Denmark, ⁴Department of Intensive Care Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

KEYWORDS

fluid overload, de-resuscitation, sepsis, heart failure, trauma, fluid management

Editorial on the Research Topic Fluid overload in the critically ill

Fluid overload in the critically ill has been a clinical concern and a topical research question in the past decades. Numerous investigations formed in the wake of two landmark trials where higher intravenous fluid volumes led to worse outcome (1, 2). The first trial enrolled adults with acute lung injury (1), whereas the latter included African children with severe infection (2). Subsequent studies in broader populations of critically ill patients have added to these findings (3, 4), and in recent years, trials on enhanced fluid strategies have emerged globally (5–7). This has challenged conventional fluid management and raised additional questions. In this Research Topic, we encouraged contributions on the various aspects of fluid overload in the critically ill.

The Research Topic comprises six papers covering early fluid resuscitation and vasopressors, fluid management in sub-populations of critically ill patients, fluid overload assessment, and de-resuscitative strategies from clinicians' perspectives.

In a narrative review, Macdonald et al. provide an overview of contemporary evidence for fluids vs. vasopressors in the early resuscitation of sepsis and septic shock. The review outlines theories for sepsis pathogenesis, including micro- and macro-circulatory alterations, and the potential hemodynamic interactions of intravenous fluids and vasopressors. Ultimately, the rationale for a trial of restricted fluids and early vasopressors in septic shock is outlined.

Fluid overload has no uniform definition, diagnostic test, or management guideline in the general critically ill population. Zeuthen et al. report the results of an international survey among 1,066 Intensive Care Unit (ICU) physicians on the assessment and treatment of fluid overload. It describes current de-resuscitative strategies in the ICU, including that most clinicians supported a weight-based definition of fluid overload (minimum 5-10% increase in body weight), and most considered fluid overload a modifiable risk for morbidity. The most frequent choice of treatment was diuretics, followed by fluid restriction.

Patients with heart failure present a particular challenge for fluid management. Lower blood pressures *via* afterload reduction may have unloading benefits, but low preload and low blood pressures may also reduce coronary flow. Thus, hemodynamic changes can be both beneficial and detrimental in this patient population. As patients with heart failure often require fluids to improve cardiac output in the initial phase, they may represent a population



who is specifically prone to to fluid overload at a later stage. In a retrospective cohort study, Dong et al. evaluated the association between fluid management and in-hospital mortality in ICU patients with sepsis and heart failure. The authors propose *fluid accumulation index (fluid balance/fluid intake ratio)* as a tool to assess fluid overload, as the fluid accumulation index was found to be a risk factor for in-hospital mortality in these patients.

Waskowski et al. included 2,158 patients admitted to ICU due to severe heart failure and/or cardiogenic shock in a retrospective cohort study. In contrast to other studies, no association between fluid overload (>5% increase in body weight) at ICU discharge and 30-day mortality was found in this population. Notably, <10% of the study population had fluid overload at ICU discharge, indicating that most of the population was already de-resuscitated at that time. In this study, open-heart surgery prior to admission, prior liver disease, and lactate at baseline were associated with fluid overload at ICU discharge, while disease severity or pre-existing kidney disease were not.

While the bulk of fluid research has focused on early intrahospital management, Jensen et al. investigated the effect of prehospital transportation on fluid administration in the first 24 h in patients with suspected infection. In this *post-hoc* analysis of a prospective observational study, the authors found that patients transported with emergency medical services received more fluid than those arriving at the hospital on their own, after adjustment for confounders. Importantly, the majority of the study population had simple infection or sepsis, and these patients are not directly represented in the Surviving Sepsis Guideline (8). Pre-hospital treatment might be worth considering in future guidelines updates.

Trauma patients have a unique pathophysiology, often characterized by hypovolemic shock followed by systemic inflammation, thus representing a separate sub-population of critically ill patients. In a retrospective study of 52 trauma patients, Wrzosek et al. found that infused fluids and fluid balance on day 2 of ICU stay were associated with increased mortality. Fluid balances and fluid input were correlated with the number of blood products infused, as well as with coagulation parameters, suggesting that hemorrhagic shock might have been a driver of excess fluid administration and poor outcome in this study.

In summary, this Research Topic covers some of the key aspects of fluid overload in the critically ill and addresses specific populations and time points, where fluid management could impact the patient's trajectory (Figure 1). We emphasize, that bias arising from e.g., confounding by indication and time-dependent exposure challenges the interpretation of the observational studies included in this Topic, and they inherently risk overestimating treatment effects (9). However, the studies underline clinical uncertainties in both definition and treatment of fluid overload, which warrants high-quality trials in these aspects.

Author contributions

TM, SW, and AM co-wrote the manuscript. All authors contributed to the article and approved the submitted version.

Acknowledgments

We appreciate the contributions of all authors and the valuable inputs from reviewers and editors.

Conflict of interest

AM is affiliated with the Department of Intensive Care at University Hospital Bern, Inselspital, which report grants from Orion Pharma, Abbott Nutrition International, B. Braun Medical AG, CSEM AG, Edwards Lifesciences Services GmbH, Kenta Biotech Ltd, Maquet Critical Care AB, Omnicare Clinical Research AG, Nestle, Pierre Fabre Pharma AG, Pfizer, Bard Medica S.A., Abbott AG, Anandic Medical Systems, Pan Gas AG Healthcare, Bracco, Hamilton Medical AG, Fresenius Kabi, Getinge Group Maquet AG, Dräger AG, Teleflex Medical GmbH, Glaxo Smith Kline, Merck Sharp and Dohme AG, Eli Lilly and Company, Baxter, Astellas, Astra Zeneca, CSL Behring, Novartis, Covidien, Phagenesis, Cytel, and Nycomed. No personal financial gain applied. SW is affiliated with the Department of Intensive Care at Nordsjællands hospital, which has received research grants from Novo Nordisk Foundation, Sygeforsikringen Danmark, Svend Andersen's Foundation, and Merchant Jakob Ehrenreich and his wife Grete Ehrenreich's Foundation. All outside the submitted

References

1. Wiedemann HP, Wheeler AP, Bernard GR, Thompson BT, Hayden D, DeBoisblanc B, et al. Comparison of two fluid-management strategies in acute lung injury. *N Engl J Med*. (2006) 354:2564–75. doi: 10.1056/NEJMoa062200

2. Maitland K, Kiguli S, Opoka RO, Engoru C, Olupot-Olupot P, Akech SO, et al. Mortality after fluid bolus in african children with severe infection. *N Engl J Med.* (2011) 364:2483–95. doi: 10.1056/NEJMoa1101549

 Messmer AS, Zingg C, Müller M, Gerber JL, Schefold JC, Pfortmueller CA. Fluid overload and mortality in adult critical care patients-a systematic review and meta-analysis of observational studies. *Crit Care Med.* (2020) 48:1862– 70. doi: 10.1097/CCM.000000000004617

4. Malbrain ML, Marik PE, Witters I, Cordemans C, Kirkpatrick AW, Roberts DJ, et al. Fluid overload, de-resuscitation, and outcomes in critically ill or injured patients: a systematic review with suggestions for clinical practice. *Anaesthesiol Intensive Ther.* (2014) 46:361–80. doi: 10.5603/AIT.2014.0060

5. Meyhoff TS, Hjortrup PB, Wetterslev J, Sivapalan P, Laake JH, Cronhjort M, et al. Restriction of intravenous fluid in ICU patients with septic shock. *N Engl J Med.* (2022) 386:2459–70. doi: 10.1056/NEJMoa2202707 work, no personal financial gain applied. TM is affiliated with the Department of Intensive Care at Rigshospitalet, which has received funding for other projects from the Novo Nordisk Foundation, Pfizer, and Fresenius Kabi, Sygeforsikringen "danmark" a and has conducted contract research for AM-Pharma (the REVIVAL trial). No personal financial gain applied. TM was the principal investigator for the CLASSIC trial (NCT03668236), SW is the principal investigator for the GODIF trial (NCT04180397), and AM is the principal investigator for the REDUCE trial (NCT04931485).

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

6. Zampieri FG, Machado FR, Biondi RS, Freitas FGR, Veiga VC, Figueiredo RC, et al. Effect of slower vs faster intravenous fluid bolus rates on mortality in critically ill patients: the BaSICS randomized clinical trial. *JAMA*. (2021) 326:830–8. doi: 10.1001/jama.2021. 11444

7. Shapiro NI, Douglas IS, Brower RG, Brown SM, Exline MC, Ginde AA, et al. Early restrictive or liberal fluid management for sepsis-induced hypotension. *N Engl J Med.* (2023)388:499–510. doi: 10.1056/NEJMoa22 12663

 Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. *Intensive Care Med.* (2021) 47:1181–247. doi: 10.1007/s00134-021-06506-y

9. Hemkens LG, Contopoulos-Ioannidis DG, Ioannidis JP. Agreement of treatment effects for mortality from routinely collected data and subsequent randomized trials: meta-epidemiological survey. *BMJ.* (2016) 352:i493. doi: 10.1136/bmj. i493